Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. covers the 2014 Annual Meeting of Stockholders held on May 22, 2014. The filing details the outcomes of three specific proposals submitted to security holders for a vote.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
The filing reports the results of three shareholder proposals:
- Proposal 1 (Election of Directors): David Green and John F. Kennedy were elected as Class II Directors for three-year terms.
- David Green: 15,028,681 votes For; 7,443,951 votes Withheld; 5,231,346 Broker Non-Votes.
- John F. Kennedy: 15,360,340 votes For; 7,112,292 votes Withheld; 5,231,346 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2014, was ratified.
- Results: 27,611,119 votes For; 77,732 votes Against; 15,127 votes Abstained.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved via a non-binding advisory vote.
- Results: 14,985,624 votes For; 7,039,763 votes Against; 447,245 votes Abstained; 5,231,346 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly limited to reporting the results of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Confirm the tenure of the newly elected directors (David Green and John F. Kennedy) extends until the 2017 annual meeting.
- Note the significant number of broker non-votes (5,231,346) recorded for the director election and executive compensation proposals.
- Review the full proxy statement for detailed executive compensation figures referenced in Proposal 3.